AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8904624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1679870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin and aerosol inhalations of colistin twice daily for 3 weeks
Number of subjects: 26
Study 1679870 — intervention group
Group type: COMPARATOR
Intervention: No anti-pseudomonas chemotherapy
Number of subjects: 26
Study 6214611 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 60
Study 6214611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30697730 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT+Emotional Engagement (EE)
Number of subjects: 40
Study 30697730 — intervention group
Group type: COMPARATOR
Intervention: PMT+Child Centred Play (CCP)
Number of subjects: 40
Study 30697730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (PMT+EE and PMT+CCP)
Number of subjects: 40
Study 27834590 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 27
Study 24304555 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Positive Psychosocial Intervention (IPPI)
Number of subjects: 180
Study 24304555 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 180
Study 24304555 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 180
Study 23975842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (666 IU/day)
Number of subjects: 101
Study 23975842 — intervention group
Group type: COMPARATOR
Intervention: Control (no cholecalciferol)
Number of subjects: 101
Study 22559269 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intra-graft administration of abciximab and verapamil followed by direct stenting (n=91)
Number of subjects: 163
Study 22559269 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI technique (n=72)
Number of subjects: 163
Study 22559269 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=72)
Number of subjects: 163
Study 22559269 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel strategy group (n=91)
Number of subjects: 163
Study 19280232 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone substitutes (allografts, ceramics, demineralized bone matrix, osteoinductive factors, autogenous platelet concentrate, mesenchymal stem cells, gene therapy)
Number of subjects: 0
Study 15741528 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal microcirculatory protection system during PCI
Number of subjects: 501
Study 15741528 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty without distal protection
Number of subjects: 501
Study 12556375 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin (one dose)
Number of subjects: 30
Study 12556375 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin (two doses every 12 hours)
Number of subjects: 30
Study 12556375 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonvitrectomized eyes)
Number of subjects: 30
Study 10997367 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 47
Study 10997367 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickened formula (0.4 g galactomannan per 100 ml diluted milk)
Number of subjects: 47
Study 8844273 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill inclination at 1 degree
Number of subjects: 10
Study 8844273 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill inclination at 4 degrees
Number of subjects: 10
Study 8844273 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill inclination at 7 degrees
Number of subjects: 10
Study 1950094 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent split influenza vaccine
Number of subjects: 149
Study 1950094 — intervention group
Group type: COMPARATOR
Intervention: Trivalent subunit influenza vaccine
Number of subjects: 149
Study 6525242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 16
Study 6525242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hyoscine
Number of subjects: 16
Study 6525242 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study 29921088 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC DLT (n = 54)
Number of subjects: 108
Study 29921088 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone DLT (n = 54)
Number of subjects: 108
Study 28092404 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice a day)
Number of subjects: 34
Study 28092404 — intervention group
Group type: COMPARATOR
Intervention: Myoinositol (1000 mg twice a day)
Number of subjects: 34
Study 25638326 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (15 mg/kg intravenously on day 1 or 2)
Number of subjects: 390
Study 25638326 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 390
Study 24408124 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal nitric oxide measurement in allergic rhinitis
Number of subjects: 175
Study 24408124 — intervention group
Group type: COMPARATOR
Intervention: Nasal nitric oxide measurement in nonallergic rhinitis
Number of subjects: 175
Study 24408124 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of nasal nitric oxide with sinus ostial obstruction in allergic rhinitis
Number of subjects: 175
Study 24408124 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of nasal nitric oxide with opacification score in allergic rhinitis
Number of subjects: 175
Study 24408124 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of nasal nitric oxide with eosinophil count in allergic rhinitis
Number of subjects: 175
Study 21948313 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotrol(®) ETT with McGrath(®)
Number of subjects: 60
Study 21948313 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotrol(®) ETT with GlideScope(®)
Number of subjects: 60
Study 21948313 — intervention group
Group type: COMPARATOR
Intervention: GlideRite(®)‐styletted standard ETT with McGrath(®)
Number of subjects: 60
Study 21948313 — intervention group
Group type: COMPARATOR
Intervention: GlideRite(®)‐styletted standard ETT with GlideScope(®)
Number of subjects: 60
Study 20014908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fu-Yuan Pellet (FYP)
Number of subjects: 225
Study 20014908 — intervention group
Group type: COMPARATOR
Intervention: Lofexidine
Number of subjects: 225
Study 17306016 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus hydrocortisone (200 mg/day)
Number of subjects: 48
Study 17306016 — intervention group
Group type: COMPARATOR
Intervention: Continuous hydrocortisone infusion (200 mg/day)
Number of subjects: 48
Study 17306016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 16047507 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 2097
Study 16047507 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI(3)
Number of subjects: 2097
Study 16047507 — intervention group
Group type: EXPERIMENTAL
Intervention: HUI(2)
Number of subjects: 2097
Study 16047507 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 2097
Study 16047507 — intervention group
Group type: EXPERIMENTAL
Intervention: eQWB
Number of subjects: 2097
Study 16047507 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS
Number of subjects: 2097
Study 12887471 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum protein analysis using SELDI technique
Number of subjects: 35
Study 12887471 — intervention group
Group type: EXPERIMENTAL
Intervention: 17.5 kDa protein abundance in stage T1 prostate cancer
Number of subjects: 35
Study 10381298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment for 52 weeks
Number of subjects: 79
Study 8730228 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (four logarithmically increasing doses)
Number of subjects: 50
Study 8730228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four logarithmically increasing doses)
Number of subjects: 50
Study 1888825 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine (300 mg nocte)
Number of subjects: 48
Study 1888825 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine (800 mg nocte)
Number of subjects: 48
Study 1888825 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine (40 mg nocte)
Number of subjects: 48
Study 1888825 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study 6337578 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride with behavior therapy (BT)
Number of subjects: 218
Study 6337578 — intervention group
Group type: COMPARATOR
Intervention: Placebo with behavior therapy (BT)
Number of subjects: 218
Study 6337578 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride with supportive psychotherapy
Number of subjects: 218
Study 6337578 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy with placebo
Number of subjects: 218
Study 31141427 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling over the anterior thigh
Number of subjects: 12
Study 31141427 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling over the knee joint
Number of subjects: 12
Study 30247524 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (B) added to chemotherapy (capecitabine (C)±mitomycin (M))
Number of subjects: 237
Study 30247524 — intervention group
Group type: EXPERIMENTAL
Intervention: CMS classification
Number of subjects: 237
Study 30247524 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (B) added to first-line capecitabine-based chemotherapy
Number of subjects: 237
Study 25896863 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based training programme for general practitioners
Number of subjects: 0
Study 25896863 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25296334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) 50,000 IU/week
Number of subjects: 96
Study 25296334 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 96
Study 21914653 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based intervention
Number of subjects: 0
Study 21914653 — intervention group
Group type: EXPERIMENTAL
Intervention: Change-based intervention
Number of subjects: 0
Study 20521904 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional worksite health promotion program
Number of subjects: 631
Study 20521904 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated consumer program
Number of subjects: 631
Study 20521904 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 631
Study 17915999 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus 3 days of AZM, 500 mg
Number of subjects: 30
Study 17915999 — intervention group
Group type: COMPARATOR
Intervention: Surgery plus 3 days of placebo
Number of subjects: 30
Study 16105155 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine
Number of subjects: 125
Study 16105155 — intervention group
Group type: COMPARATOR
Intervention: NPH
Number of subjects: 125
Study 12114037 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplementation (600 mg vitamin E, 250 mg vitamin C, and 20 mg beta‐carotene daily)
Number of subjects: 20536
Study 12114037 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20536
Study 10193713 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg
Number of subjects: 218
Study 10193713 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 218
Study 10193713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 10193713 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (all doses)
Number of subjects: 218
Study 10193713 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (75 mg and 150 mg)
Number of subjects: 218
Study 10193713 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 218
Study 7474602 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral orchiectomy and 25 mg/day of etoposide every 2 weeks for 6 months
Number of subjects: 44
Study 7474602 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral orchiectomy and 560 mg/day of estramustine phosphate for 6 months
Number of subjects: 44
Study 7474602 — intervention group
Group type: COMPARATOR
Intervention: Bilateral orchiectomy alone
Number of subjects: 44
Study 2148504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg once daily
Number of subjects: 27
Study 2148504 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa 250 mg twice daily
Number of subjects: 27
Study 108152 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllocontin tablets (12.5 mg/kg)
Number of subjects: 10
Study 108152 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllocontin tablets (12.5 mg/kg twice daily)
Number of subjects: 10
Study 108152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29322619 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-SES
Number of subjects: 2737
Study 29322619 — intervention group
Group type: COMPARATOR
Intervention: DP-SES
Number of subjects: 2737
Study 27306264 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide during altitude sojourn at 2590 m
Number of subjects: 39
Study 27306264 — intervention group
Group type: COMPARATOR
Intervention: Placebo during altitude sojourn at 2590 m
Number of subjects: 39
Study 25909149 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus gasseri KS‐13, Bifidobacterium bifidum G9‐1, and Bifidobacterium longum MM2)
Number of subjects: 32
Study 25909149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23843441 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of long-chain ω‐3 polyunsaturated fatty acids (LCω‐3PUFA)
Number of subjects: 834
Study 23843441 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher linoleic acid (ω‐6)
Number of subjects: 834
Study 20965387 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced education (four isomorphic cycles of nine e‐mails over 36 weeks)
Number of subjects: 95
Study 20965387 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 95
Study 20965387 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced education (continued after intervention)
Number of subjects: 95
Study 20965387 — intervention group
Group type: COMPARATOR
Intervention: Control (continued after intervention)
Number of subjects: 95
Study 17853036 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg intravenously 60 min before the procedure
Number of subjects: 60
Study 17853036 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg intravenously 60 min before the procedure
Number of subjects: 60
Study 17853036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 16027246 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (DC) 100 g per day (containing 88 mg flavanols)
Number of subjects: 20
Study 16027246 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (DC) 100 g per day
Number of subjects: 20
Study 16027246 — intervention group
Group type: COMPARATOR
Intervention: Flavanol-free white chocolate (WC) 90 g per day
Number of subjects: 20
Study 14619611 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with lower glycaemic index
Number of subjects: 0
Study 10643800 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg) and placebo beverage
Number of subjects: 12
Study 10643800 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo pill and alcohol (0.55 g/kg in 10% (v/v) solution)
Number of subjects: 12
Study 10643800 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill and placebo beverage
Number of subjects: 12
Study 10643800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both caffeine and alcohol
Number of subjects: 12
Study 8865536 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein C, Antithrombin III, Heparin-Cofactor II, and plasminogen levels
Number of subjects: 4000
Study 8865536 — intervention group
Group type: COMPARATOR
Intervention: Menopause status
Number of subjects: 4000
Study 8865536 — intervention group
Group type: COMPARATOR
Intervention: Pill use
Number of subjects: 4000
Study 8865536 — intervention group
Group type: COMPARATOR
Intervention: PT and PTT ratio, gender, age, smoking, body-mass index, HDL cholesterol, blood group
Number of subjects: 4000
Study 6528679 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA blood irradiation
Number of subjects: 92
Study 6528679 — intervention group
Group type: COMPARATOR
Intervention: Citrate infusion
Number of subjects: 92
Study 6528679 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 92
Study 29652271 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 μg/kg/min) administered preoperatively for 24 hours including intraoperative period
Number of subjects: 60
Study 29652271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no levosimendan)
Number of subjects: 60
Study 24894735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (3 × 1 h weekly sessions)
Number of subjects: 44
Study 24894735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance-based intervention (3 × 1 h weekly sessions)
Number of subjects: 44
Study 24894735 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 44
Study 24960268 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote robotic navigation (RRN)
Number of subjects: 157
Study 24960268 — intervention group
Group type: COMPARATOR
Intervention: Manual ablation
Number of subjects: 157
Study 22728005 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention with optimal medical therapy
Number of subjects: 2201
Study 22728005 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 2201
Study 20861588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20861588 — intervention group
Group type: COMPARATOR
Intervention: Quotient™ ADHD System (QGSS)
Number of subjects: 30
Study 20861588 — intervention group
Group type: COMPARATOR
Intervention: Lin's concordance correlation coefficient for QGSS
Number of subjects: 30
Study 20861588 — intervention group
Group type: COMPARATOR
Intervention: Lin's concordance correlation coefficient for ADHD-RS Total score
Number of subjects: 30
Study 19024339 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 40
Study 19024339 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 40
Study 16009170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate instillation (300 mL)
Number of subjects: 36
Study 16009170 — intervention group
Group type: COMPARATOR
Intervention: Control (no fluid instillation)
Number of subjects: 36
Study 12406833 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab (750 mg, three intravenous doses over 20 weeks)
Number of subjects: 24
Study 12406833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11762559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole 200 mg twice daily for 2 days, then once daily for 5 days
Number of subjects: 32
Study 11762559 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution 200 mg twice daily
Number of subjects: 32
Study 11762559 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution 200 mg once daily
Number of subjects: 32
Study 11762559 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with itraconazole
Number of subjects: 32
Study 11762559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole
Number of subjects: 32
Study 9205678 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse cyclophosphamide and prednisolone (PCYP)
Number of subjects: 54
Study 9205678 — intervention group
Group type: COMPARATOR
Intervention: Continuous oral prednisolone and cyclophosphamide followed by azathioprine (CCAZP)
Number of subjects: 54
Study 7679560 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.16 mg.kg‐1)
Number of subjects: 38
Study 7679560 — intervention group
Group type: COMPARATOR
Intervention: Diamorphine (0.08 mg.kg‐1)
Number of subjects: 38
Study 2887152 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (2 to 3 g/d, stratified according to weight)
Number of subjects: 31
Study 2887152 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 31
Study 2887152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31434737 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA/rAd5 HIV vaccine regimen
Number of subjects: 0
Study 31434737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31434737 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Env‐specific CD8+ T-cell polyfunctionality score and IgG response
Number of subjects: 0
Study 31434737 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-gp140 antibody-dependent cellular phagocytosis
Number of subjects: 0
Study 28287949 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory community theater (CT) dramas
Number of subjects: 1200
Study 27132450 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 1 μg x kg(‐1) x min(‐1) for sedation and 1 mg/mL remifentanil for analgesia with 0.05 mg/kg intravenous bolus, then continuous infusion of 0.02‐0.10 mg x kg(‐1) x h(‐1)
Number of subjects: 140
Study 27132450 — intervention group
Group type: COMPARATOR
Intervention: Midazolam for sedation only (control group)
Number of subjects: 140
Study 27132450 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 1 μg x kg(‐1) x min(‐1) for sedation and 1 mg/mL remifentanil for analgesia
Number of subjects: 140
Study 23440308 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORES after-school program
Number of subjects: 156
Study 23440308 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 156
Study 21280081 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg entacapone
Number of subjects: 33
Study 21280081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33